DiaMedica Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . DiaMedica Therapeutics
DMAC Stock  USD 5.21  0.13  2.56%   
DiaMedica Therapeutics financial statements provide useful quarterly and yearly information to potential DiaMedica Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on DiaMedica Therapeutics financial statements helps investors assess DiaMedica Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting DiaMedica Therapeutics' valuation are summarized below:
Market Capitalization
222.8 M
Earnings Share
(0.56)
We have found one hundred twenty available fundamental signals for DiaMedica Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to verify all of DiaMedica Therapeutics' prevailing performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. As of November 28, 2024, Market Cap is expected to decline to about 32.3 M. In addition to that, Enterprise Value is expected to decline to about 29.7 M

DiaMedica Therapeutics Total Revenue

500,000

Check DiaMedica Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DiaMedica Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 K, Interest Expense of 426.2 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 49.24, Dividend Yield of 0.0 or PTB Ratio of 1.72. DiaMedica financial statements analysis is a perfect complement when working with DiaMedica Therapeutics Valuation or Volatility modules.
  
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

DiaMedica Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets56.9 M54.2 M17.6 M
Slightly volatile
Short and Long Term Debt Total276 K400 K343.6 K
Slightly volatile
Other Current Liabilities1.8 M1.7 M814.3 K
Slightly volatile
Total Current Liabilities2.9 M2.8 M1.6 M
Slightly volatile
Property Plant And Equipment Net509.2 K485 K152.9 K
Slightly volatile
Accounts Payable563.1 K926 K622.4 K
Very volatile
Cash3.5 M4.5 M3.8 M
Slightly volatile
Non Current Assets Total638.8 K485 K557.5 K
Slightly volatile
Cash And Short Term Investments55.5 M52.9 M16.7 M
Slightly volatile
Net Receivables387.4 K369 K211.1 K
Slightly volatile
Common Stock Shares Outstanding34.2 M32.6 M11.6 M
Slightly volatile
Liabilities And Stockholders Equity56.9 M54.2 M17.6 M
Slightly volatile
Other Stockholder Equity174.9 M166.6 M67.2 M
Slightly volatile
Total Liabilities3.3 M3.1 M1.7 M
Slightly volatile
Property Plant And Equipment Gross614.2 K585 K171 K
Slightly volatile
Total Current Assets56.4 M53.7 M17 M
Slightly volatile
Other Current Assets431.6 K411 K148.4 K
Slightly volatile
Property Plant Equipment676.2 K644 K167.3 K
Slightly volatile
Capital Surpluse114.6 M109.2 M47 M
Slightly volatile
Net Invested Capital28 M51.1 M14.1 M
Slightly volatile
Net Working Capital27.8 M50.9 M13.9 M
Slightly volatile

DiaMedica Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization28.5 K30 K454.4 K
Slightly volatile
Other Operating Expenses22.3 M21.3 M9.2 M
Slightly volatile
Research Development13.8 M13.1 M5.7 M
Slightly volatile
Total Operating Expenses22.3 M21.3 M9.2 M
Slightly volatile
Selling General Administrative8.6 M8.2 M3.3 M
Slightly volatile
Interest Income47.1 K44.9 K20.5 K
Slightly volatile
Reconciled Depreciation21.7 K28 K12.5 K
Slightly volatile
Selling And Marketing Expenses24 K27 K29.4 K
Slightly volatile

DiaMedica Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.2 M4.7 M3.6 M
Slightly volatile
Depreciation28.5 K30 K397.4 K
Slightly volatile
Capital Expenditures22.8 K24 K46.3 K
Slightly volatile
End Period Cash Flow3.5 M4.5 M3.8 M
Slightly volatile
Stock Based Compensation876.3 K1.7 M887.4 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio49.2451.8356.7026
Slightly volatile
Days Sales Outstanding358512528
Very volatile
Invested Capital2.5 M2.6 M3 M
Slightly volatile
Average Payables600.3 K571.7 K553.2 K
Slightly volatile
Stock Based Compensation To Revenue0.991.121.2153
Slightly volatile
Capex To Depreciation0.760.83.3566
Slightly volatile
EV To Sales12.5313.1925.1151
Slightly volatile
Inventory Turnover0.230.241.4 K
Slightly volatile
Days Of Inventory On Hand1.6 K1.5 K860
Slightly volatile
Payables Turnover0.02710.03240.0298
Slightly volatile
Sales General And Administrative To Revenue4.384.935.3683
Slightly volatile
Average Inventory0.770.710.6523
Very volatile
Research And Ddevelopement To Revenue11.9210.49.6323
Very volatile
Capex To Revenue0.110.120.2989
Slightly volatile
Cash Per Share0.971.62420.9604
Slightly volatile
Days Payables Outstanding10.7 K11.3 K32.3 K
Slightly volatile
Income Quality1.050.96630.8213
Slightly volatile
Intangibles To Total Assets0.10.110.1895
Slightly volatile
Current Ratio20.2319.2668.9898
Slightly volatile
Receivables Turnover1.170.740.7533
Pretty Stable
Graham Number8.024.58195.8895
Slightly volatile
Capex Per Share7.0E-47.0E-40.0348
Slightly volatile
Average Receivables51.7 K29 K30.6 K
Pretty Stable
Revenue Per Share0.07680.05810.0689
Slightly volatile
Interest Debt Per Share0.01170.01230.0818
Slightly volatile
Debt To Assets0.0070.00741.0307
Slightly volatile
Days Of Payables Outstanding10.7 K11.3 K32.3 K
Slightly volatile
Ebt Per Ebit1.080.90930.9672
Very volatile
Quick Ratio20.2319.2668.98
Slightly volatile
Net Income Per E B T1.121.00221.0224
Very volatile
Cash Ratio1.551.63072.8553
Very volatile
Days Of Inventory Outstanding1.6 K1.5 K860
Slightly volatile
Days Of Sales Outstanding358512528
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.21.00131.0897
Slightly volatile
Fixed Asset Turnover4.924.694.9229
Slightly volatile
Debt Ratio0.0070.00741.0307
Slightly volatile
Price Sales Ratio49.2451.8356.7026
Slightly volatile
Asset Turnover0.02980.03140.0363
Slightly volatile

DiaMedica Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap32.3 M37.6 M44.4 M
Pretty Stable
Enterprise Value29.7 M33.8 M40.6 M
Pretty Stable

DiaMedica Fundamental Market Drivers

Cash And Short Term Investments52.9 M

DiaMedica Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About DiaMedica Therapeutics Financial Statements

DiaMedica Therapeutics stakeholders use historical fundamental indicators, such as DiaMedica Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although DiaMedica Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DiaMedica Therapeutics' assets and liabilities are reflected in the revenues and expenses on DiaMedica Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DiaMedica Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue39.1 K41.1 K
Cost Of Revenue30 K31.5 K
Stock Based Compensation To Revenue 1.12  0.99 
Sales General And Administrative To Revenue 4.93  4.38 
Research And Ddevelopement To Revenue 10.40  11.92 
Capex To Revenue 0.12  0.11 
Revenue Per Share 0.06  0.08 
Ebit Per Revenue(12.17)(12.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
How To Invest In DiaMedica
Details
Is DiaMedica Stock a good investment?
Details
What is DiaMedica Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Return On Assets
(0.24)
Return On Equity
(0.35)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY